Squire Patton Boggs has advised the shareholders and management team of Access Infinity, a leading provider of market access, pricing, and evidence strategy solutions to the global pharmaceutical and biotech industries, on an investment in the company by CBPE Capital. The terms have not been disclosed.
The team advising Access Infinity was led by Corporate partner Mark Yeo and senior associate Simon Ayling and included associates Victoria James and Alyssa Davies with director Emma Perez and associate Alice Jenkinson advising on tax matters.
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies worldwide, providing a suite of software and consulting services that support clients throughout the drug development lifecycle. The company’s innovative software solutions (comprising Nuro, Access Hub and Evidence Hub) and expert consulting team help pharma clients navigate complex global market access challenges, optimise pricing strategies, and deliver value to patients across diverse healthcare systems.
CBPE’s investment will support Access Infinity as it accelerates its growth strategy, further develops its technology platform, and expands its international presence. The partnership will enable the company to continue investing in talent, innovation, and service offerings for its expanding customer base, which already includes 22 of the top 25 pharma companies.
